These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18452107)

  • 1. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.
    Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P
    Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.
    Tajeddine N; Gala JL; Louis M; Van Schoor M; Tombal B; Gailly P
    Cancer Res; 2005 Aug; 65(16):7348-55. PubMed ID: 16103086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
    Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
    Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling.
    Xu Y; Rong LJ; Meng SL; Hou FL; Zhang JH; Pan G
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1057-63. PubMed ID: 27049257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.
    Xu Y; Yue Q; Wei H; Pan G
    Int J Clin Exp Pathol; 2015; 8(11):14549-55. PubMed ID: 26823776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression.
    Yao CY; Lin CC; Wang YH; Hsu CL; Kao CJ; Hou HA; Chou WC; Tien HF
    J Formos Med Assoc; 2023 Jul; 122(7):636-647. PubMed ID: 36428148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.
    Tanaka N; Wang YH; Shiseki M; Takanashi M; Motoji T
    Leuk Res; 2011 Sep; 35(9):1219-25. PubMed ID: 21550659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of PRAME gene in acute leukemia and its clinical significance].
    Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of PRAME gene in adult acute leukemia and its significance in prognosis].
    Zhou PY; Li WJ; Wei CX; Zhou Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1177-81. PubMed ID: 18088461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.
    Schenk T; Stengel S; Goellner S; Steinbach D; Saluz HP
    Genes Chromosomes Cancer; 2007 Sep; 46(9):796-804. PubMed ID: 17534929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
    Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
    J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.
    Steinbach D; Hermann J; Viehmann S; Zintl F; Gruhn B
    Cancer Genet Cytogenet; 2002 Mar; 133(2):118-23. PubMed ID: 11943337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
    Wang YY; Ye ZY; Zhao ZS; Tao HQ; Chu YQ
    Ann Surg Oncol; 2010 Jan; 17(1):89-97. PubMed ID: 19820999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
    Gutierrez-Cosío S; de la Rica L; Ballestar E; Santamaría C; Sánchez-Abarca LI; Caballero-Velazquez T; Blanco B; Calderón C; Herrero-Sánchez C; Carrancio S; Ciudad L; Cañizo C; San Miguel JF; Pérez-Simón JA
    Leuk Res; 2012 Jul; 36(7):895-9. PubMed ID: 22503131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
    Oehler VG; Guthrie KA; Cummings CL; Sabo K; Wood BL; Gooley T; Yang T; Epping MT; Shou Y; Pogosova-Agadjanyan E; Ladne P; Stirewalt DL; Abkowitz JL; Radich JP
    Blood; 2009 Oct; 114(15):3299-308. PubMed ID: 19625708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.